Company intelligence / Profile preview
Gabather AB
Stockholm, Swedengabather.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Gabather’s lead candidate GT-002 has demonstrated excellent pharmacokinetics and safety in Phase 1 trials. The company has initiated a double-blind randomized Phase 2 study with the Centre for Neuropsychiatric Schizophrenia Research to evaluate efficacy in patients with schizophrenia. Early results from EEG/fMRI target engagement studies have been positive[8].
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Centre for Neuropsychiatric Schizophrenia Research at Psychiatric Centre Glostrup, DenmarkInnovation Fund Denmark
Beyond the preview
Go deeper on Gabather AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gabather AB.